Filing Details

Accession Number:
0000904454-16-001380
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-08-23 16:43:16
Reporting Period:
2016-08-19
Filing Date:
2016-08-23
Accepted Time:
2016-08-23 16:43:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1105533 Argos Therapeutics Inc ARGS Pharmaceutical Preparations (2834) 562110007
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1598754 Public Joint Stock Co Pharmstandard Likhacevsky Drive 5 &Quot;B&Quot;
Dolgoprudny 1Z 141700
No No Yes No
1598762 S.a. International Pharmstandard 10A, Rue Henry Schnadt
Luxembourg N4 L-2530
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-08-19 53,524 $4.23 12,864,544 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-08-22 21,950 $4.26 12,886,494 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.13 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. Pharmstandard International S.A. is a wholly owned subsidiary of Public Joint Stock Company Pharmstandard. As the parent entity, Public Joint Stock Company Pharmstandard has voting power over the shares of the Issuer held by Pharmstandard International S.A.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.24 to $4.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.